Stryker biotech division hit by fraud charges in US
This article was originally published in SRA
Executive Summary
Orthopaedic specialist Stryker has said it is “disappointed” by a US federal grand jury indictment that accuses the company’s biotech division and several employees of improper marketing practices and intentionally defrauding the Food and Drug Administration1,2.